These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 19744248

  • 1. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone.
    Betteridge DJ.
    Fundam Clin Pharmacol; 2009 Dec; 23(6):675-9. PubMed ID: 19744248
    [Abstract] [Full Text] [Related]

  • 2. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
    Wilcox R, Kupfer S, Erdmann E, PROactive Study investigators.
    Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
    [Abstract] [Full Text] [Related]

  • 3. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A.
    Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
    [Abstract] [Full Text] [Related]

  • 4. PROactive: time for a critical appraisal.
    Betteridge DJ, DeFronzo RA, Chilton RJ.
    Eur Heart J; 2008 Apr; 29(8):969-83. PubMed ID: 18375395
    [Abstract] [Full Text] [Related]

  • 5. The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.
    Polonsky T, Mazzone T, Davidson M.
    Trends Cardiovasc Med; 2009 Apr; 19(3):94-9. PubMed ID: 19679266
    [Abstract] [Full Text] [Related]

  • 6. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U, Pop-Busui R, Eagle KA.
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [Abstract] [Full Text] [Related]

  • 7. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
    Haberbosch W.
    Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
    [Abstract] [Full Text] [Related]

  • 8. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.
    Davidson M, Meyer PM, Haffner S, Feinstein S, D'Agostino R, Kondos GT, Perez A, Chen Z, Mazzone T.
    Circulation; 2008 Apr 22; 117(16):2123-30. PubMed ID: 18413496
    [Abstract] [Full Text] [Related]

  • 9. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study.
    Langenfeld MR, Forst T, Hohberg C, Kann P, Lübben G, Konrad T, Füllert SD, Sachara C, Pfützner A.
    Circulation; 2005 May 17; 111(19):2525-31. PubMed ID: 15883215
    [Abstract] [Full Text] [Related]

  • 10. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14).
    Spanheimer R, Betteridge DJ, Tan MH, Ferrannini E, Charbonnel B, PROactive Investigators.
    Am J Cardiol; 2009 Jul 15; 104(2):234-9. PubMed ID: 19576353
    [Abstract] [Full Text] [Related]

  • 11. Cardiovascular risk and cardiometabolic protection: role of glitazones.
    Petrazzi L, Grassi D, Polidoro L, D'Aurelio A, Croce G, Properzi G, Tiberti S, Desideri G, Ferri C.
    J Nephrol; 2008 Jul 15; 21(6):826-35. PubMed ID: 19034866
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular manifestations of insulin resistance.
    Chahwala V, Arora R.
    Am J Ther; 2009 Jul 15; 16(5):e14-28. PubMed ID: 19114874
    [Abstract] [Full Text] [Related]

  • 13. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.
    Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N.
    Diabetes Obes Metab; 2008 Dec 15; 10(12):1221-38. PubMed ID: 18505403
    [Abstract] [Full Text] [Related]

  • 14. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G, Issa M, Vlajnic A.
    Curr Med Res Opin; 2006 Apr 15; 22(4):751-9. PubMed ID: 16684436
    [Abstract] [Full Text] [Related]

  • 15. A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control.
    Seufert J.
    Curr Med Res Opin; 2006 Apr 15; 22 Suppl 2():S39-48. PubMed ID: 16914074
    [Abstract] [Full Text] [Related]

  • 16. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.
    Nagajothi N, Adigopula S, Balamuthusamy S, Velazquez-Cecena JL, Raghunathan K, Khraisat A, Singh S, Molnar J, Khosla S, Benatar D.
    Am J Ther; 2008 Apr 15; 15(6):506-11. PubMed ID: 19127132
    [Abstract] [Full Text] [Related]

  • 17. [Evidences demonstrating the effects of anti-atherosclerotic actions of pioglitazone--special emphasis on PROactive Study and PERISCOPE Study].
    Kawamori R.
    Nihon Rinsho; 2010 Feb 15; 68(2):235-41. PubMed ID: 20158090
    [Abstract] [Full Text] [Related]

  • 18. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M, Corsi A, Di Pietro C, Bellatreccia A, Mariz S, COM06 Study Investigators.
    Nutr Metab Cardiovasc Dis; 2008 Jun 15; 18(5):373-9. PubMed ID: 17919894
    [Abstract] [Full Text] [Related]

  • 19. Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes.
    Donnelly R.
    Int J Clin Pract; 2007 Jul 15; 61(7):1160-9. PubMed ID: 17511791
    [Abstract] [Full Text] [Related]

  • 20. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study.
    Nicholls SJ, Tuzcu EM, Wolski K, Bayturan O, Lavoie A, Uno K, Kupfer S, Perez A, Nesto R, Nissen SE.
    J Am Coll Cardiol; 2011 Jan 11; 57(2):153-9. PubMed ID: 21211686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.